Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
